There are currently 25 clinical trials in Pompano Beach, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Clinical Research Center of Florida, Neurological Associates, Napa Research and Quantum Laboratories. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489
Recruiting
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Napa Research, Pompano Beach, Florida
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
NCT06181435
Recruiting
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participant... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
06/19/2024
Locations: NuLine Clinical Trial Center Site Number : 8401161, Pompano Beach, Florida
Conditions: Dermatitis Atopic
Register for Updates
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
NCT05550532
Recruiting
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate to severe anhedonia (ANH+) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Gender:
All
Ages:
Between 18 years and 74 years
Trial Updated:
06/18/2024
Locations: Quantum Laboratories, Pompano Beach, Florida
Conditions: Depressive Disorder, Major, Anhedonia
Register for Updates
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869
Recruiting
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: North Broward Hospital District, Pompano Beach, Florida
Conditions: Atrial Fibrillation
Register for Updates
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396574
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Clinical Research Center of Florida, Pompano Beach, Florida
Conditions: Migraine
Register for Updates
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
NCT05929079
Recruiting
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Clinical Research Center of Florida, Pompano Beach, Florida
Conditions: Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
Register for Updates
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
NCT05620407
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2024
Locations: Clinical Research Center of Pompano, Pompano Beach, Florida
Conditions: Systemic Lupus Erythematosus
Register for Updates
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05999799
Recruiting
This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe Atopic Dermatitis (AtD), who have previously been treated with medicated topical treatments or a biologic therapy.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: GSK Investigational Site, Pompano Beach, Florida
Conditions: Dermatitis, Atopic
Register for Updates
Study of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019
Recruiting
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Napa Research, Pompano Beach, Florida
Conditions: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
Register for Updates
Study of SFA002 in Patients With Mild to Moderate Psoriasis Plaques
NCT05642182
Recruiting
The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA004 on mild to moderate chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/18/2024
Locations: NuLine Clinical Trial Center, Pompano Beach, Florida
Conditions: Psoriasis
Register for Updates
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT04408755
Recruiting
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
04/30/2024
Locations: Clinical Research Site, Pompano Beach, Florida
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Register for Updates
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)
NCT05637801
Recruiting
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's disease. Approximately 530 subjects will be randomized to 12 months of daily treatment with either Active or Sham Sensory Stimulation Systems. Efficacy will be measured using the Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) assessment and a combined statistical test (CST) of the ADCS-ADL and the Mini-Mental State E... Read More
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
04/22/2024
Locations: Quantum Laboratories, Pompano Beach, Florida
Conditions: Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
Register for Updates